Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study
November 20, 2025
Siolta Therapeutics, a clinical-stage biotech company developing first-in-class live biotherapeutic products (LBPs), today announced positive top-line results from the Phase 2 ADORED study (Allergic Disease Onset pREvention stuDy) of STMC-103H, its lead investigational oral microbial therapy.
UCSF Congratulates Susan Lynch and Nikole Kimes, founders of Siolta.